



NEONATAL MEDICATION PROTOCOLS

OCTREOTIDE
 Created by: NCCU
 Date for review: Oct 2016

NCCU Clinical Guidelines
 KEMH/PMH
 Perth, Western Australia

DRUG:	OCTREOTIDE
PRESENTATION:	Ampoule: 100 microgram/mL Unit dose syringes: Supplied by Pharmacy.
ACTION & INDICATION:	Synthetic analogue of Somatostatin (a growth hormone inhibitor) which inhibits insulin release. Used to treat: (i) hypoglycaemia due to hyperinsulinism unresponsive to diazoxide and glucose (ii) "short bowel syndrome" (iii) chylothorax
DOSE :	Subcutaneous/intravenous: 1 - 5 microgram/kg/dose 6 - 8 hourly Titrate dose to patients requirements to a maximum dose of 10 microgram/kg/dose Intravenous infusion: For treatment of chylothorax 1 microgram/kg/hour .Titrate dose upwards as required. Maximum dose: 7 microgram/kg/hour
PREPARATION:	IV: Use undiluted solution or dilute to a strength of from 5 to 250microgram per mL ie 100microgram diluted to 20mL = 5 microgram per mL)
ADMINISTRATION:	Subcutaneous injection. Intravenous infusion.
ADVERSE EFFECTS:	Local reaction at injection site. GI side effects – vomiting, diarrhoea, abdominal discomfort.
COMMENTS:	Chyle production should decrease significantly within 24 hours Check PGL pre-dose and as requested. Refrigerate and protect from light. Diluted solution is stable for eight hours only.
REFERENCES:	Neofax 2013 BNF for Children 2013 Australian Injectable DRUGS Handbook 5 th Ed SHPA
DATE:	October 2013